{"id":8228,"date":"2023-08-04T13:31:41","date_gmt":"2023-08-04T13:31:41","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8228"},"modified":"2023-08-09T13:43:29","modified_gmt":"2023-08-09T13:43:29","slug":"new-b7-family-immune-checkpoint-proteins","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/new-b7-family-immune-checkpoint-proteins\/","title":{"rendered":"New B7 Family Immune Checkpoint Proteins"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

Targeting immune checkpoint regulators such as programmed cell death 1 (PD-1)\/PD-1 ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) has achieved notable benefits in a variety of cancers. Recently five new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7, were identified, all of them possibly being of high interest in immunotherapy research.<\/p>\n\n\n\n

B7-H3 [CD276] has a co-inhibitory function on T cells. Its expression on either tumour cells or diffuse tumour vasculature is significantly associated with an increased risk of death and bad outcome. Targeting B7-H3 not only enhances anti-tumour immunity but also inhibits tumour angiogenesis.<\/p>\n\n\n\n

B7-H4 plays a significant role in the \u201cimmune escape\u201d of tumours and is a potential therapeutic target for the treatment of cancer. It plays an important role in the T cell-mediated immune response as a negative regulator. The ligation of B7-H4 to unidentified receptors results in the inhibition of TCR-mediated T cell proliferation, cell-cycle progression and IL-2 production.<\/p>\n\n\n\n

VISTA [V-domain immunoglobulin suppressor of T cell Activation; B7-H5] is type I Ig membrane protein homologous to PD-L1. VISTA is mainly expressed on hematopoietic tissues (spleen, thymus and bone marrow) and on myeloid cells. VISTA is a new negative checkpoint regulator that potently suppresses T cell activation. It delivers a co-inhibitory impact on T cell response.  Recent publications have reported that a recombinant VISTA protein needs to be multimerized to be active as a soluble ligand. The protein VISTA (mouse):COMP (mouse) (with the extracellular domain of mouse VISTA fused to the pentamerisation domain from the cartilage oligomeric matrix protein (COMP), but not VISTA-Fc, has been shown to function as an immunosuppressive agonist in vivo<\/em> inhibiting the proliferation of CD4+ T cells. Additionally, a new function of the protein P-selectin glycoprotein ligand-1 (PSGL-1) as a new receptor for the immune checkpoint VISTA has been shown. Multimer VISTA binds PSGL-1 expressed on leukocytes at acidic pH, but not at the physiological pH 7. VISTA – PSGL-1 interaction shows that immune response can be regulated by acidic environments found in tumours.<\/p>\n\n\n\n

B7-H6 (also known as NCR3LG1) is a ligand for NK cell activating receptor NKp30. It is expressed on tumour cells but can also be induced by inflammatory stress in healthy cells. B7-H6 has been validated as a potential target for antitumour immunotherapy strategies in tumour-bearing mice. The expression of B7-H6 is significantly correlated with post-operative prognosis in cancer patients and with distant metastasis status.<\/p>\n\n\n\n

B7-H7 is widely expressed in human malignancies and its expression is associated with poor prognostic factors. Targeting B7-H7 not only benefits antitumour immunity but also inhibits tumour angiogenesis. For B7-H7, a T cell co-inhibitory role and a co-stimulatory role have been reported, most probably based on two counter receptors, one CD28H and the other unknown.<\/p>\n\n\n\n

LIT:<\/strong> New B7 family checkpoints in human cancers: L. Ni & C. Dong; Mol. Cancer Ther. 16,<\/strong> 1203 (2017) \u2022 VISTA.COMP – an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses: A. Prodeus, et al.; JCI Insight 2,<\/strong> e94308 (2017)<\/p>\n\n\n\n

NEW VISTA is an acidic pH-selective Ligand for PSGL-1<\/strong> <\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

PSGL-1 (human):Fc (human) (rec.) (Prod. No. AG-40B-0190<\/a>) binds to its ligand VISTA only at acidic pH.<\/p>\n\n\n\n

Method:<\/strong> VISTA (human):COMP (mouse) (rec.) (His) (Prod. No. AG-40B-0183<\/a>) or an unrelated protein Nampt (human) (His) (Prod. No. AG-40A-0031Y<\/a>)(Control) is coated on an ELISA plate at 1\u03bcg\/ml overnight at room temperature. PSGL-1 (human):Fc (human) (rec) (Prod. No. AG-40B-0190<\/a>) is incubated (starting at 1000ng\/ml with a twofold serial dilution) for one hour in mild acidic (pH 6.4) or neutral conditions (pH 7.4) and then detected using an anti-human Fc antibody (HRP).<\/p>\n\n\n\n

NEW: B7-H3 (human) ELISA Kit  – Biomarker for Immuno-Oncology Research<\/strong><\/h3>\n\n\n\n

The B7-H3 (human) ELISA Kit (Prod. No. AG-45B-0025<\/a>) is a sandwich ELISA for specific quantitative determination of soluble human B7-H3 (CD276) in serum, plasma and cell culture supernatants. Soluble human B7-H3 (CD276) is ectopically expressed in various cancers and its levels in serum of patients with cancer suggests it can be used as a noninvasive biomarker for diagnosis, prognosis and\/or treatment response.<\/p>\n\n\n\n

Biologically Active New B7 Family Proteins<\/strong>  <\/p>\n\n\n\n

See all Biologically Active New B7-H3 proteins here<\/a>.<\/p>\n\n\n\n

See all Biologically Active New B7-H4 proteins here<\/a>.<\/p>\n\n\n\n

See all Biologically Active New B7-H5 proteins from Chimerigen <\/a>and AdipoGen Life Sciences<\/a>.<\/p>\n\n\n\n

See all Biologically Active New B7-H6 proteins here<\/a>.<\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on adipogen.com\/new-b7-family-immune-checkpoint-proteins\/<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Recently 5 new B7 family ligands, B7-H3, B7-H4, B7-H5, B7-H6 & B7-H7, were identified, all of them possibly of high interest in immunotherapy research.<\/p>\n","protected":false},"author":13,"featured_media":8237,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,29,637],"tags":[279,7,683],"class_list":["post-8228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-immunology","category-t-cells","tag-adipogen","tag-cancer","tag-proteins"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8228"}],"version-history":[{"count":6,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8228\/revisions"}],"predecessor-version":[{"id":8284,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8228\/revisions\/8284"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8237"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}